Vaxcyte : Investor Presentation January 2022

Corporate Presentation

JANUARY 6, 2022

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the benefits of Vaxcyte's vaccine candidates; demand for Vaxcyte's vaccine candidates; the process and timing of anticipated future development of Vaxcyte's vaccine candidates, including the initiation of the VAX-24 Phase 1/2 clinical proof-of-concept study and the development of VAX-XP; the timing and availability of topline data for VAX-24; the achievement of future funding milestones; the use and availability of funds from CARB-X; the nomination of a final vaccine candidate for VAX-PG; the market opportunity for our vaccines; our expectations regarding the potential benefits, spectrum coverage and immunogenicity of our vaccine candidates; the timing of the initiation, progress and expected results of our preclinical studies, clinical trials and research and development plans; and other statements

that are not historical fact. The words "anticipate," "believe," "continue," "could," "designed," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project,"

"should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are based on Vaxcyte's current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte's product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities; Vaxcyte's reliance on third-party manufacturers; potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates; the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; sufficiency of cash and other funding to support Vaxcyte's development programs and other operating expenses; and the ongoing COVID-19 pandemic, which could materially and adversely affect Vaxcyte's business and operations. These and other risks are described more fully in Vaxcyte's filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on November 10, 2021 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. Vaxcyte undertakes no duty or obligation to update any forward- looking statements contained in this release as a result of new information, future events or changes in its expectations.

January 6, 2022

2

VAXCYTE MISSION STATEMENT

We are on a global mission to engineer high- fidelity vaccines that protect humankind from the consequences of bacterial diseases.

January 6, 2022

3

Key Corporate Highlights

Next-Generation Vaccine Company - Led by Pneumococcal Conjugate Vaccine (PCV) Franchise

Large market opportunity for PCV franchise

• Scalable PCV platform enabling broader-spectrumPCVs: VAX-24& VAX-XP
• Lead candidate: VAX-24
• • 24-valentPCV with potential to replace SOC
  • VAX-24IND clearance announced on 1/6/22
  • Anticipate Ph 2 topline immunogenicity results in adults by end of 2022(1)

	Cell-free		Disciplined target	Robust development		Aligned critical
	Protein synthesis		selection	pipeline		resources
	platform
•	Leverages site-specific	•	Targets well-defined >$7B	• Platform unlocks large	•	Strategic alignment with
	conjugation		market segment	market opportunities:		Lonza (manufacturing)
•	Permits production of	•	Honors well-understood	- VAX-A1: Novel Group A	•	Seasoned management
	"tough-to-make" antigens		PCV MOA	Strep conjugate vaccine		team, directors and advisors
•	Demonstrated speed,	•	Leverages established	- VAX-PG: Novel	• Cash, cash equivalents and
	flexibility and scalability		surrogate immune	periodontitis therapeutic		investments of $318.3M at
			endpoints and clinical	vaccine		9/30/21
			pathways

1. Guidance provided as of January 6, 2022.

January 6, 2022

4

Experienced Team, Board of Directors and Scientific Advisors

Outstanding Track Record in Vaccines and Biopharma

Management Team

	Grant Pickering, MBA		Jim Wassil, MS, MBA		Andrew Guggenhime,
	CEO & Co-founder		COO		MBA
						President & CFO

Jeff Fairman, PhD		Paul Sauer, MBA	Harp Dhaliwal, MBA
VP Research & Co-	SVP PD & Manufacturing	SVP Commercial Mfg &
founder				Supply Chain

Board of Directors

Carlos Paya, MD, PhD - Chair		Annie Drapeau		Halley Gilbert

	Peter Hirth, PhD		Michael Kamarck, PhD		Teri Loxam

Heath Lukatch, PhD		Kurt von Emster			Grant Pickering

Scientific Advisory Board

Jeff Almond, PhD	Tony Ford-Hutchinson,PhD	Emmanuel Hanon, PhD

Bill Hausdorff, PhD

Tom Monath, MD

Emmanuel Walter, MD, MPH

January 6, 2022

5